Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Only 15-40% of advanced #NSCLC patients respond to standard ICIs.
This #HealthyLungMonth, we're highlighting the need for new treatments.
Candel is testing CAN-2409, a viral immunotherapy showing promise in progressive disease despite ICI treatment.
https://www.candeltx.com/patients/#step-25
Register for BSI #ImmuneTherapies24 now & save money!
This summit will bring together sector leaders from across #ImmuneTherapies #research & will also welcome Dr @paulpetertak for an inspiring keynote 🌟
Early bird deadline: 31 October 🔗https://bit.ly/4eYp306
Big congratulations to @demishassabis John Jumper and David Baker! Amazing work, rewarded with the Nobel Prize. @GoogleDeepMind
President and CEO, @paulpetertak, MD, PhD, FMedSci, will join a panel with Sushil Patel, CEO of Replimune, at the ROTH Healthcare Opportunities Conference.
The panel will cover product differentiation, data across indications, development steps, & manufacturing capabilities.
